$BIIB (-1,07 %) --> More sales coming?
2Lun·
FDA Approves LEQEMBI® IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

investors.biogen.comFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease | Biogen
33